Trials / Completed
CompletedNCT00290563
Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)
A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK0594 in Patients With Overactive Bladder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 557 (actual)
- Sponsor
- Vyne Therapeutics Inc. · Industry
- Sex
- All
- Age
- 40 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to investigate whether a new drug may offer safe and effective treatment for patients with overactive bladder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0594 |
Timeline
- Start date
- 2006-02-21
- Primary completion
- 2007-08-01
- Completion
- 2007-09-24
- First posted
- 2006-02-13
- Last updated
- 2021-05-19
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00290563. Inclusion in this directory is not an endorsement.